Results 1 to 10 of about 467,392 (261)

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection [PDF]

Frontiers in Immunology
IntroductionSerum levels of interleukin-6 (IL-6) are increased in COVID-19 patients. IL-6 is an effective therapeutic target in inflammatory diseases and tocilizumab, a monoclonal antibody that blocks signaling via the IL-6 receptor (IL-6R), is used to ...
Juliane Lokau, Juliane Lokau, Yvonne Garbers, Manuel M. Vicente, Anna Dittrich, Stefan Meltendorf, Holger Lingel, Anja K. Münster-Kühnel, Monika Brunner-Weinzierl, Christoph Garbers, Christoph Garbers   +10 more
doaj   +2 more sources

Human retinal endothelial cells express functional interleukin-6 receptor [PDF]

Journal of Ophthalmic Inflammation and Infection, 2023
Background Interleukin (IL)-6 is an inflammatory cytokine present in the eye during non-infectious uveitis, where it contributes to the progression of inflammation.
Lisia Barros Ferreira, Liam M. Ashander, Binoy Appukuttan, Yuefang Ma, Keryn A. Williams, Giles Best, Justine R. Smith   +6 more
doaj   +2 more sources

Evaluation of interleukin‐1 and interleukin‐6 receptor antagonists in a murine model of acute lung injury [PDF]

Experimental Physiology
The acute exudative phase of acute respiratory distress syndrome (ARDS), a severe form of respiratory failure, is characterized by alveolar damage, pulmonary oedema, and an exacerbated inflammatory response.
Émilie Meunier, Mélissa Aubin vega, Damien Adam, Anik Privé, Mohammad Ali Mohammad Nezhady, Isabelle Lahaie, Christiane Quiniou, Sylvain Chemtob, Emmanuelle Brochiero   +8 more
doaj   +2 more sources

Interleukin-6 Receptor Gene rs1800795 Polymorphism and Expression of Interleukin-6 in Gingival Tissue in Patients with Periodontitis [PDF]

Microorganisms
Periodontitis is a multifactorial inflammatory disease. This chronic periodontal disease is caused by a bacterial infection in the gums, which triggers a host inflammatory response.
Małgorzata Mazurek-Mochol, Tobias Bonsmann, Damian Malinowski, Karol Serwin, Michał Czerewaty, Krzysztof Safranow, Andrzej Pawlik   +6 more
doaj   +2 more sources

A Mendelian Randomization Study and Experimental Validation Investigating the Potential Relationship Among Interleukin‐6 Receptor Subunit Beta, Obesity, and Alzheimer's Disease [PDF]

Brain and Behavior
Objective This study employs Mendelian randomization (MR) aimed at systematically evaluating the relationship among interleukin‐6 receptor subunit beta, obesity, and Alzheimer's disease (AD). We conducted animal studies to validate the reliability of the
Yu Liu, Nan Song, Qun Wang, Peng Cui, Dongyu Min   +4 more
doaj   +2 more sources

Interleukin-1 Beta rs16944 and rs1143634 and Interleukin-6 Receptor rs12083537 Single Nucleotide Polymorphisms as Potential Predictors of COVID-19 Severity [PDF]

Pathogens
Host genetic variation has been recognized as a key predictor of diverse clinical sequelae among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients.
Inas A. Ahmed, Taghrid G. Kharboush, Hiba S. Al-Amodi, Hala F. M. Kamel, Ehab Darwish, Asmaa Mosbeh, Hossam A. Galbt, Amal M. Abdel-Kareim, Shimaa Abdelsattar   +8 more
doaj   +2 more sources

Treatment of severe covid-19 with interleukin 6 receptor inhibition [PDF]

BMJ Medicine, 2022
Stephen Burgess, Dipender Gill, Skanda Rajasundaram   +2 more
doaj   +2 more sources

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update [PDF]

Annals of the Rheumatic Diseases, 2023
Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine.
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes WJ Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L Hyrich, Annamaria Iagnocco, John D Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen   +43 more
openaire   +13 more sources

Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease [PDF]

Blood, 1991
Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways.
M, Jücker, H, Abts, W, Li, R, Schindler, H, Merz, A, Günther, C, von Kalle, M, Schaadt, T, Diamantstein, A C, Feller   +9 more
openaire   +3 more sources

Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. [PDF]

PLoS ONE, 2013
Multicentric Castleman Disease is largely driven by increased signaling in the pathway for the plasma cell growth factor interleukin-6. We hypothesized that interleukin-6/interleukin-6 receptor/gp130 polymorphisms contribute to increased interleukin-6 ...
Katie Stone, Emily Woods, Susann M Szmania, Owen W Stephens, Tarun K Garg, Bart Barlogie, John D Shaughnessy, Brett Hall, Manjula Reddy, Antje Hoering, Emily Hansen, Frits van Rhee   +11 more
doaj   +1 more source